AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01714011
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours.
Trial: NCT01714011
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
Trial: NCT03099538
Drug: Ixekizumab
RxNorm normalized name: Ixekizumab
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injection
Trial: NCT01276730
Drug: Cisplatin and radiation
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
Trial: NCT01410630
Drug: FLT
RxNorm normalized name: FLT201
DrugBank: FLT201 (DB18419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mCi IV
Trial: NCT00004314
Drug: aminomidazole carboxamide riboside
RxNorm normalized name: Aminoimidazole carboxamide
DrugBank: Aminoimidazole carboxamide (DB06143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02989714
Drug: Interleukin-2
RxNorm normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
Trial: NCT02989714
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
Trial: NCT00993070
Drug: Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.025% topical capsaicin applied 4 times per day for 8 weeks
Trial: NCT01390805
Drug: Valaciclovir Hydrochloride.
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00999037
Drug: Sevelamer Carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily renvela (800 mg tid with meals) x 12 weeks
Trial: NCT02379247
Drug: BYL-719 (alpelisib)
RxNorm normalized name: Bylvay
DrugBank: Odevixibat (DB16261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral PI3K inhibitor
Trial: NCT02379247
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV taxane
Trial: NCT03867994
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03867994
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03867994
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03047265
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
Trial: NCT03047265
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
Trial: NCT04842162
Drug: indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: indocyanine green (INFRACYANINE© 25mg/10mL).
Trial: NCT04135820
Drug: BPI-7711
RxNorm normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPI-7711 180 mg
Trial: NCT00403039
Drug: Ranibizumab (Lucentis )
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01474668
Drug: GDC-0941
RxNorm normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose\\n \\n\\n\\n\\n
Trial: NCT01767415
Drug: Indigo carmine
RxNorm normalized name: indigo carmine
DrugBank: Indigotindisulfonic acid (DB11577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
Trial: NCT01817751
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT01817751
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT01817751
Drug: sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by mouth
Trial: NCT00555477
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg tablet by mouth once a day
Trial: NCT00450723
Drug: Isosulfan blue
RxNorm normalized name: Isosulfan Blue
DrugBank: Isosulfan blue (DB09136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
Trial: NCT01535495
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol XL 120mg by mouth once daily
Trial: NCT03610724
Drug: lymphodepleting chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to tisagenlecleucel infusion, each subject underwent lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
Trial: NCT01535859
Drug: Cabergoline
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
Trial: NCT00998556
Drug: Bromocriptine
RxNorm normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
Trial: NCT02549651
Drug: tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
Trial: NCT01470170
Drug: Alfentanil
RxNorm normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Give Alfentanil before TCI Propofol sedative bronchoscope
Trial: NCT02951962
Drug: Crestor 20mg
RxNorm normalized name: Crestor 20mg Tablet
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyperlipidemia
Trial: NCT02039362
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
Trial: NCT00742248
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
Trial: NCT00742248
Drug: Formoterol
RxNorm normalized name: Formoterol
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
Trial: NCT02536313
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT04784728
Drug: Lidocaine topical system 1.8%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine patch
Trial: NCT00037570
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02198443
Drug: Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: (TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
Trial: NCT02198443
Drug: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
Trial: NCT04825795
Drug: DPP4-inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prescription of DPP4-inhibitor during the period between the two coronary CT scan
Trial: NCT04825795
Drug: No DPP4-inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No prescription of DPP4-inhibitor during the period between the two coronary CT scan
Trial: NCT00873340
Drug: Interferon-1beta (Betaseron, BAY86-5046)
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
Trial: NCT00288249
Drug: Sagopilone (BAY86-5302, ZK 219477)
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Trial: NCT01924091
Drug: Dapivirine gel
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01924091
Drug: Dapivirine film
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03919292
Drug: Neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
Trial: NCT03919292
Drug: Divalproex Sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
Trial: NCT04116528
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg/kg
Trial: NCT04116528
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
Trial: NCT00288249
Drug: Sagopilone (BAY86-5302, ZK 219477)
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Trial: NCT00288249
Drug: Sagopilone (BAY86-5302, ZK 219477)
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Trial: NCT04116203
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Manufacturer's standard 500 mg. Submission Control No.:128147
Trial: NCT01470170
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
Trial: NCT02691572
Drug: Intrathecal bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 12.5 mg will be administered in the subarachnoid space.
Trial: NCT02691572
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral paracetamol 1 gm/8 h starting 4 h after surgery.
Trial: NCT01452256
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-6 Vol %
Trial: NCT01452256
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIVA to achieve BIS value of 40-60
Trial: NCT03060681
Drug: Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
Trial: NCT04209543
Drug: Estetrol
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol oral tablet: administered orally once daily
Trial: NCT00288249
Drug: Sagopilone (BAY86-5302, ZK 219477)
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Trial: NCT00216463
Drug: ISIS 301012 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
Trial: NCT00216463
Drug: ISIS 301012 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
Trial: NCT00216463
Drug: ISIS 301012 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg subcutaneous injection - every week for 13 weeks
Trial: NCT00216463
Drug: ISIS 301012 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg subcutaneous injection - every week for 13 weeks
Trial: NCT00216463
Drug: ISIS 301012 or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 200 mg subcutaneous injection - every week for 13 weeks
Trial: NCT02411162
Drug: Combination therapy GSK2894512 Cream A + GSK2894512 Cream B
RxNorm normalized name: Amphotericin B Cream
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm\^2 of skin.
Trial: NCT02411162
Drug: Combination therapy Vehicle Cream A + Vehicle Cream B
RxNorm normalized name: amphotericin B Topical Cream
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
Trial: NCT02098512
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~* 42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~* 84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~* 105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
Trial: NCT01020734
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01020734
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01020734
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02077920
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~* Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~* Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving
Trial: NCT00609986
Drug: insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140.
Trial: NCT00609986
Drug: NPH Insulin or glargine insulin and aspartame insulin
RxNorm normalized name: Insulin Glargine
DrugBank: Aspartame (DB00168)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL